Already have an account?


Login with an existing Projects In Knowledge account
New to Projects In Knowledge?


Register today to customize your experience.
Log In
Don't have an account yet? Click here to register



Register for Free
Already have an account? Click here to log in



Enter your current email address.  Your email address will be your user name, and where you will receive confirmation of this registration.



Forgot Password

Please Enter your email address.




  Terms & Conditions                                                                                                                                     

Privacy Policy

Projects In Knowledge is committed to protecting the privacy and confidentiality of visitors to our Web site. While Projects In Knowledge does not require that you provide us with personally identifiable information in order to visit our Web site, please note that in order to participate in the continuing medical education activities that we provide, it will be necessary for you to register with us and provide this information.

About this Privacy Policy
www.projectsinknowledge.com is our Web site for physicians and allied health care professionals, although it is open to non-professionals as well. The purpose of projectsinknowledge.com is to provide continuing medical education for healthcare professionals, and is intended for use only by a licensed healthcare professional.

Projects In Knowledge is the name we use to refer to our entire company, even though our formal corporate name is Projects In Knowledge, Inc. When we refer to ourselves as "we" or "Projects In Knowledge," we mean our company, Projects In Knowledge, Inc., including any subsidiary that we control (for example, a subsidiary that we own). We may share information among our subsidiaries that we own or control, but it is always protected under the terms of this privacy policy.

This privacy policy applies only to the Projects In Knowledge Web site. You should read the privacy policy at each Web site that you visit after you leave our site. We are not responsible for how other Web sites treat your privacy, once you leave the Projects In Knowledge site.

Privacy Policy Changes
If we change our privacy policy, we will post those changes on this page. Users should check this policy to keep abreast of any changes.

Information We Collect
In this section of our privacy policy, we discuss the different types of information we may collect about you, and the ways in which we collect them.

Information We Collect from Unregistered Visitors
Visitors to our Web site can access the Web site's home page and browse the site without disclosing any personally identifiable information. We do track information provided to us by your browser, including the Web site you came from (known as the "referring URL"), the type of browser you use, the time and date of access, and other information that does not personally identify you.

Information We Collect When You Register
Customers registering on our Web site for continuing medical education activities we provide are asked to provide us with identifying information, such as name, contact information, and other identifying information. On our registration screens, we clearly label which information is required for registration, and which information is optional and may be given at your discretion.

On our registration screens you will also find a “Burning Question” field. Submission of a “Burning Question” is completely voluntary. By submitting a “Burning Question,” you grant Projects In Knowledge the right to share it with faculty to consider as they prepare their continuing medical education presentations.

Listserves
When you are using a listserve—or member-only discussion board— on our Web site, you are posting a message and your user name, which is available for all registered members to see. You should not post any information to our listserves you want to keep private. It is a condition of our Web site that when participating in a listserve, you do not:

  • Restrict or inhibit any other user from using the listserve
  • Post or transmit any unlawful, threatening, abusive, libelous, defamatory, obscene, vulgar, pornographic, profane or indecent information of any kind, including, without limitation, any transmission constituting or encouraging conduct that would constitute a criminal offense, give rise to civil liability or otherwise violate any local, state, national or foreign law
  • Post or transmit any information, software or other material which violates or infringes upon the rights of others, including material which constitutes an invasion of privacy or infringement of publicity rights or which is protected by copyright, trademark or other proprietary right, or derivative works thereof, without first obtaining permission from the owner or right holder
  • Post or transmit any information, software or other material which contains a virus or other harmful component
  • Post, or transmit, or in any way exploit any information, software or other material for commercial purposes which contains advertising, promotions or marketing

By sending a message through the listserve, you grant Projects In Knowledge the non-exclusive right and license to display, copy, publish, distribute, transmit, print, and use such information. Projects In Knowledge reserves the right to terminate your access to, and use of, the listserve if you do not abide by these conditions.

Use of Cookies
Cookies are a technology used by the Projects In Knowledge Web site to identify a user as the user moves through the Web site. Your browser allows us to place some information on your computer's hard drive that identifies the computer you are using. We use cookies to track your usage throughout our Web site.

Your Web browser can be set to allow you to control whether you will accept cookies, reject cookies, or to notify you each time a cookie is sent to you. If your browser is set to reject cookies, Web sites that are cookie-enabled will not recognize you when you return to the Web site, and some Web site functionality may be lost. The Help section of your browser will tell you how to prevent your browser from accepting cookies.

Although cookies do not normally contain personally identifiable information, if you are a registered user we may associate your registration information with cookies our Web site places on your computer's hard drive. Associating a cookie with your registration data allows us to offer increased personalization and functionality. For example, you can elect to have our Web site "remember" you and bypass the registration process each time you register for one of our educational activities. Without cookies, this functionality would not be possible. Projects In Knowledge does not currently employ cookies for this use, but is considering it to make our registration processes more efficient for you.

Children's Privacy
Projects In Knowledge's Web site is designed and intended for use by adults, and is not intended for, nor designed to be used by children under the age of 18, or any other unlicensed, untrained individuals. We do not collect personally identifiable information from any person we know is a child under the age of 18.

Uses We Make of Information
In this section of our privacy policy, we identify the ways we may use information about you that we have collected.

Aggregate Data
We create aggregate data about visitors to our Web site for activity development and improvement. We also use it for market analysis. We may provide information from our Web site in aggregate form, with identifying information removed, to third parties. For example, we may tell a third party what percentage of our registered users reside in a particular geographical area. When aggregated information is provided, we pool it from many individual records and strip it of any data that could be used to identify an individual before it is used. Any third party that receives aggregated data must agree not to attempt to re-identify the people it belongs to. Projects In Knowledge does not sell any user data to any third party for commercial purposes.

Third Parties
In addition to aggregate information (discussed previously), we may share some kinds of information with third parties as described below.

  • Business Transfers: If we transfer a business unit (such as a subsidiary) or an asset (such as a Web site) to another company, we will require them to honor the applicable terms of this privacy policy.

Protection of Information
In this section of our privacy policy, we discuss the security measures we take to protect information that we have collected about you.

General Policies
We have implemented technology and security policies, rules and other measures to protect the personal data that we have under our control from unauthorized access, improper use, alteration, unlawful or accidental destruction, and accidental loss. We also protect your information by requiring that all our employees and others who have access to or are associated with the processing of your data respect your confidentiality. In addition, we have appropriate security measures in place in our physical facilities to protect against the loss or misuse of information at our site that we have collected from you.

Projects In Knowledge Employees
Projects In Knowledge employees are required to keep customer information private, as a condition of their employment with the company. Only selected, authorized Projects In Knowledge employees are permitted to access your registration information.
Employees are required to sign a confidentiality agreement. All employees and contractors must abide by our privacy policy, and those who violate that policy are subject to disciplinary action, up to and including termination of their employment and legal action.

Privacy Questions or Concerns about Our Web Site
For privacy questions or concerns about the Projects In Knowledge Web site, please contact privacy@projectsinknowledge.com.

Revision date: This policy was last updated on September 30, 2003.



New and Noteworthy


  • Tumor Immunology — Musculoskeletal Immune-Related Adverse Events – Webcast
  • Musculoskeletal toxicities associated with immune checkpoint inhibitor therapy may be difficult to recognize as such given their similarity in presentation to the aches and pains of pre-existing osteoarthritis or other chronic debilitating disease. Join Leonard H. Calabrese, DO, as he teaches clinicians how ... more >>
    L. Calabrese, DO
  • Breast Cancer — HR-Positive Advanced or Metastatic Breast Cancer: Use and Sequencing of Kinase Inhibitors – @Point of Care Chapter
  • Approved cyclin dependent kinase 4/6 (CDK4/6) inhibitors—including abemaciclib, palbociclib, and ribociclib—in combination with endocrine therapy are now considered standard of care for first-line treatment of patients with hormone receptor (HR)-positive human epidermal growth factor receptor 2 (HER2)- ... more >>
    H. Burstein, MD, PhD
  • Multiple Sclerosis — Case Study: Treatment of a Patient With Relapsing MS During the Covid-19 Pandemic – @Point of Care Chapter
  • In patients with relapsing forms of multiple sclerosis (MS), there may be underlying progression in the absence of relapse activity. Choosing to initiate treatment with a high-efficacy disease-modifying therapy (DMT) is one strategy to address such accumulation of disability. In addition, in the context of a ... more >>
    R. Bermel, MD
  • Alzheimer's Disease — Alzheimer’s Disease: From Diagnosis to Treatment, Change Is Coming – BreakingMED
  • Recent Alzheimer’s disease research has poised the field for a watershed period in diagnosis and treatment, which may begin as early as this year. This shifting clinical landscape in Alzheimer’s research includes blood tests to identify possible biomarkers, the first FDA-approved tau PET ligand, and the ... more >>
    V. Abramson, MD
  • Diabetes — SGLT2 Inhibitors Morning Commute: A Mechanistic Explanation of Renal Benefit – Podcast
  • Sodium-glucose cotransporter 2 (SGLT-2) inhibition has shown efficacy beyond glycemic control. In this episode, Drs. Vivian Fonseca and George Bakris discuss diagnosing kidney disease and mechanisms of action for SGLT-2 inhibitors, and the renal benefit of these treatments for patients with and without ... more >>
    V. Fonseca, MD, FRCP
  • Breast Cancer — Case Study: Management of a Patient With Previously Untreated Metastatic PD-L1 Positive TNBC – @Point of Care Chapter
  • Triple negative breast cancer (TNBC) is more aggressive, associated with poorer prognosis, and has fewer treatment options than other subtypes of breast cancer. In recent years, two immunotherapies have been approved in combination with chemotherapy for the first-line treatment of advanced or metastatic TNBC ... more >>
    E. Hamilton, MD
  • Diabetes — SGLT2 Inhibitors Morning Commute: Optimizing Benefit in CKD Management – Podcast
  • In this podcast, our faculty build on the growing evidence of benefit of using SGLT-2 inhibitors for the prevention and slowing the progression of chronic kidney disease in patients with and without type 2 diabetes. The ultimate question though is how can these treatments be incorporated into clinical ... more >>
    V. Fonseca, MD, FRCP
  • Diabetes — SGLT-2 Inhibitors Morning Commute: CKD Benefit in Diabetic and Non-Diabetic Patients – Podcast
  • The clinical data for the use of sodium-glucose cotransporter 2 (SGLT-2) inhibitors for controlling diabetes and the renal benefit of these treatments are compelling. In this episode, our faculty takes a deeper dive into the evidence for their use.
    V. Fonseca, MD, FRCP
  • Tumor Immunology — Immuno-Oncology @Point of Care: Cardiovascular Immune-Related Adverse Events – Webcast
  • Cardiovascular toxicities of immune checkpoint inhibitors are rare but serious adverse events that need to be identified rapidly and treated appropriately. Clinician who use immunotherapies to treat their adult patients with cancer must effectively recognize and manage these toxicities. Join Joshua K. Sabari, ... more >>
  • Stroke Prevention — Patient With Atrial Fibrillation at High Risk for Stroke or Thromboembolism Who Underwent Percutaneous Intervention for Acute Coronary Syndrome – Webcast
  • Patients with atrial fibrillation who undergo percutaneous intervention to treat acute coronary syndrome need highly personalized monitoring and treatment decision-making to manage the ongoing risks of stroke or thromboembolism, bleeding, and recurrent cardiac ischemic event following percutaneous ... more >>
  • State of the Science: Multiple Sclerosis Innovations
  • State of the Science: Multiple Sclerosis Innovations provides comprehensive and up-to-date best practices in multiple sclerosis management. This includes innovative webcasts derived from major scientific conferences synthesized for the practicing clinician, interactive practice-based cases, and articles from ... more >>
    A. Cross, MD
    P. Peck, Editor-in-Chief
  • Master Class: Chronic Lymphocytic Leukemia
  • Master Class: Chronic Lymphocytic Leukemia (CLL) is designed to highlight relevant, practical advances in the treatment of CLL using a modular structure to provide an in-depth review of best practices with multiple complementary activities, including video webcasts with expert clinical specialists, case ... more >>
    B. Cheson, MD, FACP, FAAAS
  • The Art & Science of Heart Failure Management
  • The Art & Science of Heart Failure Management is designed to provide new information based on breaking medical news, new data presented at medical meetings, and case studies on current and emerging management strategies on the most up-to-date evidence-based medicine and clinical trial results in heart failure ... more >>
    J. Udelson, MD
  • Pulmonology Mastery in COPD
  • Pulmonology Mastery in COPD is designed to provide new information based on breaking medical news, new data presented at medical meetings, and case studies on current and emerging management strategies on the most up-to-date evidence-based medicine and clinical trial results in COPD. The curriculum includes ... more >>
    B. Make, MD
  • Mastery of Medicine in Diabetes Management
  • Mastery of Medicine in Diabetes Management is designed to provide new information based on breaking medical news, new data presented at medical meetings, and case studies on current and emerging management strategies on the most up-to-date evidence-based medicine and clinical trial results in diabetes ... more >>
    V. Fonseca, MD, FRCP
  • Clinical Context: Stroke Prevention in Atrial Fibrilation
  • Clinical Context: Stroke Prevention in
    Atrial Fibrillation
    is designed to provide up-to-date information on patient identification, risk factors, and current and emerging treatments and best practices in the management of atrial fibrillation.

    The curriculum includes:
    • 6 case studies
    • MedPage Today meeting
    ...
    more >>
    C. Yancy, MD, MSc
  • Hematology Mastery in Multiple Myeloma
  • Hematology Mastery in Multiple Myeloma is designed to provide new information based on breaking medical news, new data presented at medical meetings, and case studies on current and emerging management strategies on the most up-to-date evidence-based medicine and clinical trial results in multiple myeloma. ... more >>
    N. Raje, MD
  • Rheumatology Mastery in Rheumatoid Arthritis
  • Rheumatology Mastery in Rheumatoid Arthritis is designed to provide new information based on breaking medical news, new data presented at medical meetings, and case studies on current and emerging management strategies on the most up-to-date evidence-based medicine and clinical trial results in rheumatoid ... more >>
    M. Husni, MD, MPH
  • Neurology Mastery in Multiple Sclerosis
  • Neurology Mastery in Multiple Sclerosis is designed to provide new information based on breaking medical news, new data presented at medical meetings, and case studies on current and emerging management strategies on the most up-to-date evidence-based medicine and clinical trial results in multiple sclerosis. ... more >>
    J. Bowen, MD
  • Rheumatology Mastery In Ankylosing Spondylitis
  • Rheumatology Mastery in Ankylosing Spondylitis is designed to provide new information based on breaking medical news, new data presented at medical meetings, and case studies on current and emerging management strategies on the most up-to-date evidence-based medicine and clinical trial results in ankylosing ... more >>
    J. Reveille, MD
  • Ovarian Cancer @Point of Care
  • Ovarian cancer is often advanced at the time of diagnosis. Although most patients respond to initial treatment, relapse is common. With the approval of new therapies and better biomarkers of response, health outcomes for women with advanced ovarian cancer have improved significantly.
    B. Monk, MD, FACS, FACOG
  • Pulmonary Arterial Hypertension @Point of Care
  • Pulmonary arterial hypertension (PAH) is a rare disorder associated with significant morbidity and mortality. Three PAH treatment pathways or targets have been identified—the endothelin pathway, the nitric oxide pathway, and the prostacyclin pathway. In 1995 the FDA approved the first treatment specifically ... more >>
    R. Channick, MD
  • Bipolar Disorder @Point of Care
  • Bipolar disorder is a common mental illness that can have a devastating impact on people’s lives without effective treatment. Important developments in the understanding of bipolar disorder and its treatment have occurred in the past few years, with several new medications and formulations developed and ... more >>
    M. Thase, MD
  • Classical Hodgkin Lymphoma @Point of Care
  • Classical Hodgkin lymphoma (CHL) has a high cure rate with available therapies - nearly 90% - yet advances continue to be made to individualize therapy, minimize the risk of late toxicity, and expand therapeutic options. Current first-line treatment strategies for patients with early- and advanced-stage CHL ... more >>
    C. Moskowitz, MD
  • Nontuberculous Mycobacterial Lung Disease @Point of Care
  • Nontuberculous mycobacterial (NTM) lung disease, a condition of progressive lung damage caused by mycobacterial species other than those that cause tuberculosis or leprosy, is occurring with increasing frequency in the United States. Characterized by difficulties in diagnosis, non-FDA-approved treatment ... more >>
    N. Schluger, MD
  • Heart Failure @Point of Care
  • Heart failure is a significant health burden and, with increasing comorbidities and the aging of the population, this burden is likely to worsen especially in certain populations. Guideline-directed medical therapies have been shown to reduce morbidity and mortality in patients with heart failure, but are ... more >>
    G. Fonarow, MD
  • Alzheimer's Disease @Point of Care
  • This @Point of Care is a comprehensive, continually updated resource developed to enhance compliance to established clinical guidelines to improve screening and timely diagnosis of Alzheimer’s disease (AD) and to support current best practices of managing the symptoms of AD.
    R. Turner, MD, PhD
  • Atopic Dermatitis @Point of Care
  • Atopic dermatitis (AD) is a common inflammatory skin disease that affects both children and adults, and recent advances in the understanding of the immune and inflammatory processes involved in AD pathogenesis have led to the development and approval of novel therapies for the treatment of this disease. With ... more >>
    L. Eichenfield, M.D.
  • Hepatocellular Carcinoma @Point of Care
  • This @Point of Care provides a comprehensive, continually updated resource to the clinical care team with relevant and current evidence-based medicine and clinical trial data for approved and emerging therapies to help tailor treatment based on patient characteristics in order to improve the management of ... more >>
    G. Abou-Alfa, MD, MBA
  • Tumor Immunology — Musculoskeletal Immune-Related Adverse Events – Webcast
  • Musculoskeletal toxicities associated with immune checkpoint inhibitor therapy may be difficult to recognize as such given their similarity in presentation to the aches and pains of pre-existing osteoarthritis or other chronic debilitating disease. Join Leonard H. Calabrese, DO, as he teaches clinicians how ... more >>
    L. Calabrese, DO
  • Renal Cell Carcinoma — Renal Cell Carcinoma: Case Study on the Long-Term Management and Care of Patients With Durable Response to Immunotherapy – Webcast
  • As immune checkpoint inhibitor therapies prolong survival, collaborative management of immune-related adverse events is becoming an increasingly important topic for providers who care for patients with cancer. Immune-related adverse events pose unique challenges because they may affect organ systems ... more >>
  • Stroke Prevention — Patient With Atrial Fibrillation at High Risk for Stroke or Thromboembolism Who Underwent Percutaneous Intervention for Acute Coronary Syndrome – Webcast
  • Patients with atrial fibrillation who undergo percutaneous intervention to treat acute coronary syndrome need highly personalized monitoring and treatment decision-making to manage the ongoing risks of stroke or thromboembolism, bleeding, and recurrent cardiac ischemic event following percutaneous ... more >>
  • Diabetes — SGLT2 Inhibitors Morning Commute: Optimizing Benefit in CKD Management – Podcast
  • In this podcast, our faculty build on the growing evidence of benefit of using SGLT-2 inhibitors for the prevention and slowing the progression of chronic kidney disease in patients with and without type 2 diabetes. The ultimate question though is how can these treatments be incorporated into clinical ... more >>
    V. Fonseca, MD, FRCP
  • Diabetes — SGLT2 Inhibitors Morning Commute: A Mechanistic Explanation of Renal Benefit – Podcast
  • Sodium-glucose cotransporter 2 (SGLT-2) inhibition has shown efficacy beyond glycemic control. In this episode, Drs. Vivian Fonseca and George Bakris discuss diagnosing kidney disease and mechanisms of action for SGLT-2 inhibitors, and the renal benefit of these treatments for patients with and without ... more >>
    V. Fonseca, MD, FRCP
  • Tumor Immunology — Immuno-Oncology @Point of Care: Cardiovascular Immune-Related Adverse Events – Webcast
  • Cardiovascular toxicities of immune checkpoint inhibitors are rare but serious adverse events that need to be identified rapidly and treated appropriately. Clinician who use immunotherapies to treat their adult patients with cancer must effectively recognize and manage these toxicities. Join Joshua K. Sabari, ... more >>
  • Diabetes — SGLT-2 Inhibitors Morning Commute: CKD Benefit in Diabetic and Non-Diabetic Patients – Podcast
  • The clinical data for the use of sodium-glucose cotransporter 2 (SGLT-2) inhibitors for controlling diabetes and the renal benefit of these treatments are compelling. In this episode, our faculty takes a deeper dive into the evidence for their use.
    V. Fonseca, MD, FRCP
  • Tumor Immunology — Immuno-Oncology @Point of Care: Hepatic Immune-Related Adverse Events – Webcast
  • Liver toxicity may occur as an immune-related adverse event in patients receiving checkpoint protein inhibition immunotherapy. Knowing how to effectively recognize and manage liver toxicity and other immune-related adverse events is essential for clinicians administering checkpoint inhibitor therapies to ... more >>
    J. Weber, MD, PhD
  • Tumor Immunology — Immuno-Oncology @Point of Care: Hematologic Immune-Related Adverse Events – Webcast
  • Anemia and thrombocytopenia are the most common hematologic immune-related adverse events associated with checkpoint protein inhibition immunotherapy. These and other immune-related adverse events emerge from the unique mechanism of action of checkpoint inhibitors and must be addressed differently than ... more >>
    J. Weber, MD, PhD
  • Neurology Care Considerations — Neurology Journal Club – Podcast
  • How has the Covid-19 pandemic affected amyotrophic lateral sclerosis (ALS) patients? In this Journal Club podcast our faculty discusses several papers showing how the virus may affect ALS patients as well as what they are seeing in their clinics.
    R. Bedlack, Jr, MD, PhD, FAAN
  • Cardiology Care Considerations — Treatment of an Elderly Patient at High Risk for Stroke During the Covid-19 Pandemic – Case Study
  • The Covid-19 pandemic has affected all aspects of healthcare. This case illustrates the treatment of a patient diagnosed with atrial fibrillation in the spring of 2020, and highlights both best practice for the treatment of atrial fibrillation and considerations of the impact SARS-CoV-2 can have on patients ... more >>
    P. Dorian, MD
  • COPD — Case Study: Triple Therapy for a Newly Diagnosed Patient With Severe COPD – Case Study
  • Treatment with long-acting bronchodilators (long-acting muscarinic antagonists [LAMAs] and long-acting beta-2 agonists [LABAs]) is the cornerstone of pharmacologic therapy in patients with chronic obstructive pulmonary disease (COPD) who have high symptom burdens. The decision to add an inhaled corticosteroid ... more >>
  • Heart Failure — Patient With Worsening HFrEF and Multiple Hospitalizations – Case Study
  • Patients with heart failure (HF) with reduced ejection fraction should be managed using guideline-directed medical therapy, which includes agents that block the renin-angiotensin system, such as angiotensin converting enzymes inhibitors, angiotensin receptor blockers, or angiotensin receptor-neprilysin ... more >>
    J. Udelson, MD
  • Ovarian Cancer — Combination First-Line Maintenance Therapy in Ovarian Cancer – Case Study
  • The landscape of first-line maintenance therapy for advanced ovarian cancer has rapidly evolved. Whereas options were previously limited to olaparib for patients with BRCA mutations and bevacizumab for those without, two new poly (ADP-ribose) polymerase (PARP) inhibitor-based regimens have been approved as ... more >>
    L. Randall, MD, MAS
  • Heart Failure — Patient With Worsening HFrEF and Prediabetes – Case Study
  • Patients with heart failure with reduced ejection fraction (HFrEF) should be managed using guideline-directed medical therapy, and include use of agents that modulate all pathways known to affect HF outcomes. This includes evidence-based beta blockers and agents that inhibit the renin-angiotensin-aldosterone ... more >>
    J. Butler, MD, MPH, MBA
  • Asthma — Case Study: Investigational Single-Inhaler Triple Therapy for Uncontrolled Asthma – Case Study
  • Asthma is a heterogeneous disease in which treatment with inhaled corticosteroids (ICS), with or without a long-acting beta-2 agonist (LABA) bronchodilator, is highly effective. Yet, up to 40% of patients remain uncontrolled after stepwise increases in therapy. Even with the availability of add-on biologics ... more >>
    W. Soong, MD
  • Asthma — Case Study: Management of a Patient With Severe Eosinophilic Asthma – Case Study
  • Severe asthma may remain uncontrolled with inhaled corticosteroids and a long-acting bronchodilator, despite optimal treatment and good adherence, and management often requires use of periodic or maintenance oral corticosteroids. Type 2 inflammation, characterized by the presence of interleukin (IL)-4, IL-5, ... more >>
    J. Corren, MD
  • Metastatic Melanoma — Checkpoint Inhibitor Therapy for Newly Diagnosed Stage IV Melanoma – Case Study
  • Immunotherapy with immune checkpoint inhibitors is the current standard of care for the first-line treatment of metastatic melanoma. Combination immunotherapy with an anti-CTLA-4 agent and an anti-PD-1 agent can yield improved outcomes, but comes with the risk of increased grade 3/4 treatment-related adverse ... more >>
    A. Pavlick, DO, MBA
  • Heart Failure — Optimizing Treatment for a Patient With Hypertension and HFrEF – Case Study
  • Patients with heart failure with reduced ejection fraction should be managed using recent clinical trial outcomes and guideline-directed medical therapy (GDMT), which include agents that block the renin-angiotensin-aldosterone system. This case illustrates the real-life clinical scenario of a patient who ... more >>
    K. Ferdinand, MD
  • Multiple Sclerosis — Managing RRMS Patient who Converted to SPMS – Case Study
  • This case illustrates the management of a patient who progresses from clinically isolated syndrome to relapsing multiple sclerosis (MS) and, eventually, secondary progressive MS (SPMS). It highlights treatment considerations for each stage of disease, with attention to the options that have been approved in ... more >>
    P. Coyle, MD

    We appreciate our customers and hold ourselves to the highest privacy standards.

    Access My Information or Delete My Information